Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	MDPI 2020

Παρόμοια τεκμήρια

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
ανά: Laura C. Zanetti-Domingues, κ.ά.
Έκδοση: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
ανά: Zanetti-Domingues, LC, κ.ά.
Έκδοση: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
ανά: Laura C. Zanetti-Domingues, κ.ά.
Έκδοση: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
ανά: Xu H, κ.ά.
Έκδοση: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
ανά: M. Pérez-Capó, κ.ά.
Έκδοση: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
ανά: Lihua Huang, κ.ά.
Έκδοση: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
ανά: Lu Yang, κ.ά.
Έκδοση: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
ανά: Yao Li, κ.ά.
Έκδοση: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
ανά: J.-H. Lee, κ.ά.
Έκδοση: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
ανά: Cornelius Hempel, κ.ά.
Έκδοση: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
ανά: Igor Makhlin, κ.ά.
Έκδοση: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
ανά: Katri Vaparanta, κ.ά.
Έκδοση: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
ανά: Tasia Amelia, κ.ά.
Έκδοση: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
ανά: Barnabas Irmer, κ.ά.
Έκδοση: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
ανά: Aude I. Ségaliny, κ.ά.
Έκδοση: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
ανά: Panupong Mahalapbutr, κ.ά.
Έκδοση: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
ανά: Ramya Lakshmi Rajendran, κ.ά.
Έκδοση: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
ανά: Shannon S. Zhang, MD, κ.ά.
Έκδοση: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
ανά: Kenichi Suda, κ.ά.
Έκδοση: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
ανά: Xingyuan Li, κ.ά.
Έκδοση: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
ανά: Zhenfang Du, κ.ά.
Έκδοση: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
ανά: Kinlin L Chao, κ.ά.
Έκδοση: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
ανά: Rocío Mato-Basalo, κ.ά.
Έκδοση: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
ανά: Marcin Skrzypski, κ.ά.
Έκδοση: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
ανά: Keigo Kobayashi
Έκδοση: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
ανά: Daniel B Costa, κ.ά.
Έκδοση: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
ανά: Xuedi Zhang, κ.ά.
Έκδοση: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
ανά: Zhe Zhang, κ.ά.
Έκδοση: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
ανά: Tim Fischer, κ.ά.
Έκδοση: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
ανά: K. K. Laktionov, κ.ά.
Έκδοση: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
ανά: Tatsuki Shibuta, κ.ά.
Έκδοση: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
ανά: Hao Huang
Έκδοση: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
ανά: Sassan Hafizi
Έκδοση: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
ανά: Kenji Hanamura, κ.ά.
Έκδοση: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
ανά: Ichiro N. Maruyama
Έκδοση: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
ανά: Jihene Elloumi-Mseddi, κ.ά.
Έκδοση: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
ανά: Nathaniel J. Myall, MD, κ.ά.
Έκδοση: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
ανά: D. D. SAKAEVA
Έκδοση: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
ανά: Soomin Kim, κ.ά.
Έκδοση: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
ανά: Wu Z, κ.ά.
Έκδοση: (2019-10-01)